| Trial ID: | L0432 |
| Source ID: | NCT04328077
|
| Associated Drug: |
TERN-101
|
| Title: |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered TERN-101 Tablets in Adult Patients With Presumed Non-Cirrhotic
|
| Acronym: |
--
|
| Status: |
Not recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
NASH - Nonalcoholic Steatohepatitis
|
| Interventions: |
Drug: TERN-101;Other: Placebo
|
| Outcome Measures: |
Subject incidence of adverse events for TERN-101 versus placeboPercent change from baseline in ALT for TERN-101 versus placebo at 12 weeks;Plasma concentration of TERN-101 - AUC;Plasma concentration of TERN-101 - Cmax;Plasma concentration of TERN-101 - Tmax;Plasma concentration of TERN-101 - t1/2
|
| Sponsor/Collaborators: |
Terns, Inc.
|
| Gender: |
All
|
| Age: |
18 Years75 Years
|
| Phases: |
Phase 2
|
| Enrollment: |
101
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
|
| Start Date: |
13/03/2020
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
17 August 2021
|
| Locations: |
United States
|
| URL: |
https://clinicaltrials.gov/show/NCT04328077
|
